{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:00:06Z","timestamp":1785412806821,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"publisher","award":["IN607B2020\/11"],"award-info":[{"award-number":["IN607B2020\/11"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014569","name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","doi-asserted-by":"publisher","award":["SEFH21\/22"],"award-info":[{"award-number":["SEFH21\/22"]}],"id":[{"id":"10.13039\/501100014569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aripiprazole (ARI) is an atypical antipsychotic which is a substrate of P-glycoprotein (P-gp), a transmembrane glycoprotein that plays a crucial role in eliminating potentially harmful compounds from the organism. ARI once-monthly (AOM) is a long-acting injectable form which improves treatment compliance. Genetic polymorphisms in <jats:italic>ABCB1<\/jats:italic> may lead to changes in P-gp function, leading to individual differences in drug disposition. The present study aims to determine how the different variants of the three most prevalent SNPs of the <jats:italic>ABCB1<\/jats:italic> gene affect plasma concentrations of ARI, of its active metabolite dehydroaripiprazole (DHA) and ARI\/DHA ratio in patients under AOM treatment. The metabolizing state of the two main aripiprazole metabolizing enzymes (CYP2D6 and CYP3A4) were considered to specifically study the effect of P-gp on plasma concentrations of the parent compound and its active metabolite. The study found a clear relationship between the genotypes found for the different <jats:italic>ABCB1<\/jats:italic> SNPs and the ARI\/DHA ratio. Specifically, patients with GG genotype in G2677T have almost twice the ratio compared to TT genotype. Similarly, this increase is also found in C3435T with 1.4-fold and in C1236T with 1.6-fold for the same genotypes. Regarding haplotypes, significant differences were obtained between CC-GG-CC and TT-TT-TT patients, with an 87.9% higher ratio in patients with the CC-GG-CC haplotype. There was a clear trend towards lower ARI concentrations and higher DHA concentrations when the presence of mutated T alleles increases. The <jats:italic>ABCB1<\/jats:italic> gene could be a good partner along with CYP2D6 and CYP3A4 genotyping in conjunction with monitoring ARI plasma concentrations.<\/jats:p>","DOI":"10.1038\/s41598-024-84192-8","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T16:19:29Z","timestamp":1736439569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations"],"prefix":"10.1038","volume":"15","author":[{"given":"Francisco Jos\u00e9","family":"Toja-Camba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Vidal-Millares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Dur\u00e1n-Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Hermelo-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Carracedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalla","family":"Maro\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ramudo-Cela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zarra-Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anxo","family":"Fern\u00e1ndez-Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mondelo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"84192_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","volume":"1003","author":"K Aihara","year":"2004","unstructured":"Aihara, K. et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 1003, 9\u201317 (2004).","journal-title":"Brain Res."},{"key":"84192_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1592\/phco.24.2.212.33145","volume":"24","author":"TR Argo","year":"2004","unstructured":"Argo, T. R., Carnahan, R. M. & Perry, P. J. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 24, 212\u2013228 (2004).","journal-title":"Pharmacotherapy"},{"key":"84192_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/pharmaceutics13070935","volume":"13","author":"FJ Toja-Camba","year":"2021","unstructured":"Toja-Camba, F. J. et al. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics. Pharmaceutics 13, 935 (2021).","journal-title":"Pharmaceutics"},{"key":"84192_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke, C. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51, 9\u201362 (2018).","journal-title":"Pharmacopsychiatry"},{"key":"84192_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152\u2013162 (1976).","journal-title":"Biochim. Biophys. Acta"},{"key":"84192_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","volume":"1141","author":"X Liu","year":"2019","unstructured":"Liu, X. ABC family transporters. Adv. Exp. Med. Biol. 1141, 13\u2013100 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"84192_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cpt.2670","volume":"112","author":"KS Taskar","year":"2022","unstructured":"Taskar, K. S. et al. Clinical relevance of hepatic and renal P-gp\/BCRP inhibition of drugs: An international transporter consortium perspective. Clin. Pharmacol. Ther. 112, 573\u2013592 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"84192_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/316817a0","volume":"316","author":"JR Riordan","year":"1985","unstructured":"Riordan, J. R. et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316, 817\u2013819 (1985).","journal-title":"Nature"},{"key":"84192_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1476-5381.2011.01385.x","volume":"164","author":"H-D Yoo","year":"2011","unstructured":"Yoo, H.-D. et al. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10\/*10. Br. J. Pharmacol. 164, 433\u2013443 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"84192_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/14622416.8.1.29","volume":"8","author":"C Kimchi-Sarfaty","year":"2007","unstructured":"Kimchi-Sarfaty, C. et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8, 29\u201339 (2007).","journal-title":"Pharmacogenomics"},{"key":"84192_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","volume":"82","author":"H Gurney","year":"2007","unstructured":"Gurney, H. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33\u201340 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"84192_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.taap.2016.03.008","volume":"298","author":"K Miyata","year":"2016","unstructured":"Miyata, K., Nakagawa, Y., Kimura, Y., Ueda, K. & Akamatsu, M. In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines. Toxicol. Appl. Pharmacol. 298, 40\u201347 (2016).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"84192_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"FJ Sharom","year":"2008","unstructured":"Sharom, F. J. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9, 105\u2013127 (2008).","journal-title":"Pharmacogenomics"},{"key":"84192_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/hmg\/ddh099","volume":"13","author":"K Tang","year":"2004","unstructured":"Tang, K., Wong, L. P., Lee, E. J. D., Chong, S. S. & Lee, C. G. L. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13, 783\u2013797 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"84192_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","volume":"122","author":"C Belmonte","year":"2018","unstructured":"Belmonte, C. et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122, 596\u2013605 (2018).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"84192_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.11.55","volume":"12","author":"T Moons","year":"2011","unstructured":"Moons, T., De Roo, M., Claes, S. & Dom, G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12, 1193\u20131211 (2011).","journal-title":"Pharmacogenomics"},{"key":"84192_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1600-0404.2006.00761.x","volume":"115","author":"C Simon","year":"2007","unstructured":"Simon, C. et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol. Scand. 115, 232\u2013242 (2007).","journal-title":"Acta Neurol. Scand."},{"key":"84192_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cellsig.2017.01.001","volume":"31","author":"SW Kim","year":"2017","unstructured":"Kim, S. W. et al. Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cell. Signal. 31, 124\u2013134 (2017).","journal-title":"Cell. Signal."},{"key":"84192_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbagen.2015.12.011","volume":"1860","author":"V Lopes-Rodrigues","year":"2016","unstructured":"Lopes-Rodrigues, V. et al. Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. Biochim. Biophys. Acta BBA Gen. Subj. 1860, 618\u2013627 (2016).","journal-title":"Biochim. Biophys. Acta BBA Gen. Subj."},{"key":"84192_CR20","unstructured":"Table of Substrates, Inhibitors and Inducers, FDA, F. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. FDA (2024)."},{"key":"84192_CR21","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473\u20133478 (2000).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"84192_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","volume":"59","author":"KM Kirschbaum","year":"2010","unstructured":"Kirschbaum, K. M. et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59, 474\u2013479 (2010).","journal-title":"Neuropharmacology"},{"key":"84192_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/pharmaceutics16010104","volume":"16","author":"FJ Toja-Camba","year":"2024","unstructured":"Toja-Camba, F. J. et al. Towards precision medicine in clinical practice: Alinity C vs. UHPLC-MS\/MS in plasma aripiprazole determination. Pharmaceutics 16, 104 (2024).","journal-title":"Pharmaceutics"},{"key":"84192_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle, K. E. et al. Standardizing CYP 2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin. Transl. Sci. 13, 116\u2013124 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"84192_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00007691-200302000-00016","volume":"25","author":"ML Bernal","year":"2003","unstructured":"Bernal, M. L., Sinues, B., Fanlo, A. & Mayayo, E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 25, 107 (2003).","journal-title":"Ther. Drug Monit."},{"key":"84192_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","volume":"13","author":"DL Kroetz","year":"2003","unstructured":"Kroetz, D. L. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481\u2013494 (2003).","journal-title":"Pharmacogenetics"},{"key":"84192_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/FTD.0000000000000070","volume":"36","author":"T Suzuki","year":"2014","unstructured":"Suzuki, T. et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 36, 651\u2013655 (2014).","journal-title":"Ther. Drug Monit."},{"key":"84192_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","volume":"18","author":"C Rafaniello","year":"2018","unstructured":"Rafaniello, C. et al. The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogen. J. 18, 422\u2013430 (2018).","journal-title":"Pharmacogen. J."},{"key":"84192_CR29","unstructured":"SmPC Abilify Maintena, Otsuka Pharmaceuticals. ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, for intramuscular use [package insert]. Tokyo (Japan): Otsuka Pharmaceuticals Co. Ltd.; 2015. Revised: Dec\/2020 (2024)."},{"key":"84192_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2009.01.011","volume":"110","author":"J-S Wang","year":"2009","unstructured":"Wang, J.-S. et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr. Res. 110, 90\u201394 (2009).","journal-title":"Schizophr. Res."},{"key":"84192_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M. & Nies, A. T. Impact of Genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin. Pharmacokinet. 54, 709\u2013735 (2015).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84192-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T17:03:06Z","timestamp":1736442186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84192-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84192"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84192-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1521"}}